These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6629549)

  • 1. Adverse drug reactions--again.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1983 Sep; 21(9):447-50. PubMed ID: 6629549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
    Benjamin DM; Pendrak RF
    J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmaceutical care of patients with diabetes mellitus and its relationship to clinical pharmacy].
    Vlcek J; Malý J; Dosedel M
    Vnitr Lek; 2009 Apr; 55(4):384-8. PubMed ID: 19449755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, implementation and evaluation of a clinical decision support system to prevent adverse drug events.
    Del Fiol G; Rocha BH; Nohama P
    Stud Health Technol Inform; 2000; 77():740-4. PubMed ID: 11187651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International reporting of adverse drug reactions: the WHO program.
    Olsson S
    Semin Dermatol; 1989 Jun; 8(2):72-4. PubMed ID: 2641718
    [No Abstract]   [Full Text] [Related]  

  • 7. [Classification and profile of adverse drug effects].
    Cordonnier M
    Bull Soc Belge Ophtalmol; 2007; (304):15-6. PubMed ID: 17718223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
    Lehner JP; Meyer F; Juillet Y
    Therapie; 2001; 56(4):335-9. PubMed ID: 11677849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The practicing physician as generator and user of adverse reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):385-9. PubMed ID: 3733289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug name recognition and classification in biomedical texts. A case study outlining approaches underpinning automated systems.
    Segura-Bedmar I; Martínez P; Segura-Bedmar M
    Drug Discov Today; 2008 Sep; 13(17-18):816-23. PubMed ID: 18602492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Children's questions: a mechanism for cognitive development.
    Chouinard MM
    Monogr Soc Res Child Dev; 2007; 72(1):vii-ix, 1-112; discussion 113-26. PubMed ID: 17394580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Patient safety and risk management].
    Schrappe M
    Med Klin (Munich); 2005 Aug; 100(8):478-85. PubMed ID: 16096729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The incidence of drug side effects with reference to organ systems. Experience of the spontaneous reporting system of the Swiss Drug Side Effect Center and Comprehensive Drug Monitoring].
    Kuhn M; Hartmann K; Maibach R; Capaul R; Gartmann JC
    Ther Umsch; 1993 Jan; 50(1):8-12. PubMed ID: 8378869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conflicts of interest in medical science: peer usage, peer review and 'CoI consultancy'.
    Charlton BG
    Med Hypotheses; 2004; 63(2):181-6. PubMed ID: 15236772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing adverse drug reactions in the general population.
    Pezalla E
    Manag Care Interface; 2005 Oct; 18(10):49-52. PubMed ID: 16265935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.